Genetic polymorphisms in the thioredoxin 2 (TXN2) gene and risk for spina bifida

American Journal of Medical Genetics, Part A

Volumn 149, Issue 2, 2009, Pages 155-160

  Wen, Shu ^a   Lu, Wei ^a   Zhu, Huiping ^a   Yang, Wei ^b   Shaw, Gary M ^b   Lammer, Edward J ^b   Islam, Ana ^a   Finnell, Richard H ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Ins del polymorphism; Re sequencing; Spina bifida; Thioredoxin 2; TXN2

Indexed keywords

THIOREDOXIN 2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INFANT; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; SPINA BIFIDA; TRANSCRIPTION INITIATION;

CALIFORNIA; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HISPANIC AMERICANS; HUMANS; INFANT; INFANT, NEWBORN; MITOCHONDRIAL PROTEINS; NEURAL TUBE DEFECTS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SPINAL DYSRAPHISM; THIOREDOXINS; TRANSCRIPTION, GENETIC;

MUS;

EID: 59849125876     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.32589     Document Type: Article

References (33)

1. Barber R, Shalat S, Hendricks K, Joggerst B, Larsen R, Suarez L, Finnell R. 2000. Investigation of folate pathway gene polymorphisms and the incidence of neural tube defects in a Texas Hispanic population. Mol Genet Metab 70:45-52.
2. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, Hong SX, Correa A. 1999. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N. Engl J Med 341:1485-1490.
3. Blom HJ, Shaw GM, den Heijer M, Finnell RH. 2006. Neural tube defects and folate: Case far from closed. Nat Rev Neurosci 7:724-731.
4. Botto LD, Yang Q. 2000. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol 151:862-877.
5. Cebrian A, Pharoah PD, Ahmed S, Smith PL, Luccarini C, Luben R, Redman K, Munday H, Easton DF, Dunning AM, Esteller M, Ponder BA. 2006. Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer. Cancer Res 66:1225-1233.
6. Chekmenev DS, Haid C, Kel AE. 2005. P-Match: transcription factor binding site search by combining patterns and weight matrices. Nucleic Acids Res 33:W432-W437.
7. Chen Y, Cai J, Murphy TJ, Jones DP. 2002. Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells. J Biol Chem 277:33242-33248.
8. Chi H, Sarkisian MR, Rakic P, Flavell RA. 2005. Loss of mitogen-activated protein kinase kinase kinase 4 (MEKK4) results in enhanced apoptosis and defective neural tube development. Proc Natl Acad Sci USA 102:3846-3851.
9. Croen LA, Shaw GM, Jensvold NG, Harris JA. 1991. Birth defects monitoring in California: A resource for epidemiological research. Paediatr Perinat Epidemiol 5:423-427.
10. Czeizel AE, Dudas I. 1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832-1835.
11. Damdimopoulos AE, Miranda-Vizuete A, Pelto-Huikko M, Gustafsson JA, Spyrou G. 2002. Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death. J Biol Chem 277:33249-33257.
12. Detrait ER, George TM, Etchevers HC, Gilbert JR, Vekemans M, Speer MC. 2005. Human neural tube defects: Developmental biology, epidemiology, and genetics. Neurotoxicol Teratol 27:515-524.
13. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-74.
14. Hansen JM, Zhang H, Jones DP. 2006. Mitochondrial thioredoxin-2 has a key role in determining tumor necrosis factor-alpha-induced reactive oxygen species generation, NF-kappaB activation, and apoptosis. Toxicol Sci 91:643-650.
15. Harris MJ, Juriloff DM. 1999. Mini-review: Toward understanding mechanisms of genetic neural tube defects in mice. Teratology 60:292-305.
16. Husemoen LL, Toft U, Fenger M, Jorgensen T, Johansen N, Linneberg A. 2006. The association between atopy and factors influencing folate metabolism: Is low folate status causally related to the development of atopy? Int J Epidemiol 35:954-961.
17. Kibar Z, Capra V, Gros P. 2007. Toward understanding the genetic basis of neural tube defects. Clin Genet 71:295-310.
18. Lwin H, Yokoyama T, Date C, Yoshiike N, Kokubo Y, Tanaka H. 2002. Are the associations between life-style related factors and plasma total homocysteine concentration different according to polymorphism of 5,10- methylenetetrahydrofolate reductase gene (C677T MTHFR)? A cross-sectional study in a Japanese rural population. J Epidemiol 12:126-135.
19. Martin LJ. 2006. Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65:1103-1110.
20. Maulik N, Das DK. 2008. Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. Biochim Biophys Acta 780:1368-1382.
21. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 338:131-137.
22. Nonn L, Williams RR, Erickson RP, Powis G. 2003. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol 23:916-922.
23. Oestergaard MZ, Tyrer J, Cebrian A, Shah M, Dunning AM, Ponder BA, Easton DF, Pharoah PD. 2006. Interactions between genes involved in the antioxidant defence system and breast cancer risk. Br J Cancer 95:525-531.
24. Rozen S, Skaletsky H. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365-386.
25. Schulman J, Edmonds LD, McClearn AB, Jensvold N, Shaw GM. 1993. Surveillance for and comparison of birth defect prevalences in two geographic areas-United States, 1983-88. MMWR CDC Surveill Summ 42:1-7.
26. Shaw GM, Rozen R, Finnell RH, Wasserman CR, Lammer EJ. 1998. Maternal vitamin use, genetic variation of infant methylenetetrahydrofolate reductase, and risk for spina bifida. Am J Epidemiol 148:30-37.
27. Song J, Mangold M, Suske G, Geltinger C, Kanazawa I, Sun K, Yokoyama KK. 2001. Characterization and promoter analysis of the mouse gene for transcription factor Sp4. Gene 264:19-27.
28. Tang LS, Finnell RH. 2003. Neural and orofacial defects in Folp1 knockout mice [corrected]. Birth Defects Res A Clin Mol Teratol 67:209-218.
29. Tang LS, Wlodarczyk BJ, Santillano DR, Miranda RC, Finnell RH. 2004. Developmental consequences of abnormal folate transport during murine heart morphogenesis. Birth Defects Res A Clin Mol Teratol 70:449-458.
30. Udler M, Maia AT, Cebrian A, Brown C, Greenberg D, Shah M, Caldas C, Dunning A, Easton D, Ponder B, Pharoah P. 2007. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 25:3015-3023.
31. Wallin R, Rossi F, Loeser R, Key LL Jr. 1990. The vitamin K-dependent carboxylation system in human osteosarcoma U2-OS cells. Antidotal effect of vitamin K1 and a novel mechanism for the action of warfarin. Biochem J 269:459-464.
32. Wong RL, Wlodarczyk BJ, Min KS, Scott ML, Kartiko S, Yu W, Merriweather MY, Vogel P, Zambrowicz BP, Finnell RH. 2008. Mouse Fkbp8 activity is required to inhibit cell death and establish dorso-ventral patterning in the posterior neural tube. Hum Mol Genet 17:587-601.
33. Zhu H, Wicker NJ, Shaw GM, Lammer EJ, Hendricks K, Suarez L, Canfield M, Finnell RH. 2003. Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab 78:216-221.